Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


22.07.2019

1 Ann Oncol
1 Ann Surg
1 Ann Surg Oncol
2 Ann Thorac Surg
3 Anticancer Res
1 Arch Bronconeumol
3 BMC Cancer
1 Br J Cancer
3 Cancer
1 Cancer Res
3 Cancer Sci
2 Chest
1 Clin Cancer Res
9 Clin Lung Cancer
1 Clin Nucl Med
3 Eur J Cancer
1 Eur Respir J
1 Int J Cancer
3 Int J Radiat Oncol Biol Phys
1 J Cancer Res Clin Oncol
1 J Nucl Med
1 J Surg Oncol
1 J Thorac Cardiovasc Surg
4 J Thorac Oncol
2 JAMA Oncol
1 Lancet Oncol
2 Lancet Respir Med
30 Lung Cancer
1 Mol Cancer Ther
1 Mol Carcinog
2 Nat Med
3 Oncogene
2 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. KUDO Y, Haymaker C, Zhang J, Reuben A, et al
    Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer.
    Ann Oncol. 2019 Jul 8. pii: 5529670. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg

  2. CAO LL, Lu J, Xie JW, Zheng CH, et al
    Comment on "A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Nonsmall-cell Lung Cancer".
    Ann Surg. 2019;270:e46-e47.
    PubMed     Text format    


    Ann Surg Oncol

  3. LEE JH, Shin KM, Lee SY, Hong MJ, et al
    Genetic Variant of Notch Regulator DTX1 Predicts Survival After Lung Cancer Surgery.
    Ann Surg Oncol. 2019 Jul 16. pii: 10.1245/s10434-019-07614.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  4. STIRLING RG, Zalcberg J
    FDG-PET follow up of Non-Small Cell Lung Cancer: Not dead yet.
    Ann Thorac Surg. 2019 Jul 6. pii: S0003-4975(19)30993.
    PubMed     Text format    

  5. SEDER CW, Basu S, Ramsay T, Rocco G, et al
    A Prolonged Air Leak Score for Lung Cancer Resection: An Analysis of the STS GTSD.
    Ann Thorac Surg. 2019 Jul 16. pii: S0003-4975(19)31034.
    PubMed     Text format     Abstract available


    Anticancer Res

  6. RODRIGUEZ-CORDOVA RJ, Gutierrez-Valenzuela CA, Bojang P, Esquivel R, et al
    Differential Response of BEAS-2B and H-441 Cells to Methylene Blue Photoactivation.
    Anticancer Res. 2019;39:3739-3744.
    PubMed     Text format     Abstract available

  7. GEROGIANNI I, Pitaraki E, Jagirdar RM, Kouliou O, et al
    2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Anticancer Res. 2019;39:3809-3814.
    PubMed     Text format     Abstract available

  8. TAMIYA M, Tamiya A, Suzuki H, Moriizumi K, et al
    Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Anticancer Res. 2019;39:3923-3929.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  9. MARTIN-ONTIYUELO C, Sanchez-Font A, Gimeno E, Suarez-Pinera M, et al
    Hypermetabolic Bone on (18)F-FDG-PET/CT in a Patient with Lung Cancer: Is it Always Metastasis?
    Arch Bronconeumol. 2019 Jul 15. pii: S0300-2896(19)30281.
    PubMed     Text format    


    BMC Cancer

  10. YU J, Hu Y, Xu Y, Wang J, et al
    LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features.
    BMC Cancer. 2019;19:263.
    PubMed     Text format     Abstract available

  11. LI J, Shen C, Wang X, Lai Y, et al
    Prognostic value of TGF-beta in lung cancer: systematic review and meta-analysis.
    BMC Cancer. 2019;19:691.
    PubMed     Text format     Abstract available

  12. CHANTHARASAMEE J, Poungvarin N, Danchaivijitr P, Techawatanawanna S, et al
    Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    BMC Cancer. 2019;19:701.
    PubMed     Text format     Abstract available


    Br J Cancer

  13. GAO F, Alwhaibi A, Artham S, Verma A, et al
    Endothelial Akt1 loss promotes prostate cancer metastasis via beta-catenin-regulated tight-junction protein turnover.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0110.
    PubMed     Text format     Abstract available


    Cancer

  14. CHEN Y, Zhang R, Wang L, Correa AM, et al
    Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32366.
    PubMed     Text format     Abstract available

  15. WANG H, Ou Q, Li D, Qin T, et al
    Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32372.
    PubMed     Text format     Abstract available

  16. WAN X, Luo X, Tan C, Zeng X, et al
    First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32368.
    PubMed     Text format     Abstract available


    Cancer Res

  17. LU YX, Ju HQ, Liu ZX, Chen DL, et al
    ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis.
    Cancer Res. 2018;78:1972-1985.
    PubMed     Text format     Abstract available


    Cancer Sci

  18. ITO T, Nakamura A, Tanaka I, Tsuboi Y, et al
    CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.
    Cancer Sci. 2019;110:2284-2295.
    PubMed     Text format     Abstract available

  19. FAN CM, Wang JP, Tang YY, Zhao J, et al
    circMAN1A2 could serve as a novel serum biomarker for malignant tumors.
    Cancer Sci. 2019;110:2180-2188.
    PubMed     Text format     Abstract available

  20. WU Y, Jamal M, Xie T, Sun J, et al
    Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer.
    Cancer Sci. 2019 Jul 6. doi: 10.1111/cas.14125.
    PubMed     Text format     Abstract available


    Chest

  21. WIENER RS
    POINT: Can Shared Decision-Making of Physicians and Patients Improve Outcomes in Lung Cancer Screening? Yes.
    Chest. 2019;156:12-14.
    PubMed     Text format    

  22. SLATORE CG
    COUNTERPOINT: Can Shared Decision-Making of Physicians and Patients Improve Outcomes in Lung Cancer Screening? No.
    Chest. 2019;156:15-17.
    PubMed     Text format    


    Clin Cancer Res

  23. DEVARAKONDA S, Sankararaman S, Herzog B, Gold KA, et al
    Circulating Tumor DNA Profiling in Small Cell Lung Cancer Identifies Potentially Targetable Alterations.
    Clin Cancer Res. 2019 Jul 12. pii: 1078-0432.CCR-19-0879.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  24. TIAN S, Zhang X, Jiang R, Pillai RN, et al
    Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.
    Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30156.
    PubMed     Text format     Abstract available

  25. BORKENHAGEN JF, Bergom CR, Rapp CT, Klawikowski SJ, et al
    Dosimetric Predictors of Cardiotoxicity in Thoracic Radiotherapy for Lung Cancer.
    Clin Lung Cancer. 2019 Jun 5. pii: S1525-7304(19)30141.
    PubMed     Text format     Abstract available

  26. SAKAKIBARA-KONISHI J, Kitai H, Ikezawa Y, Hatanaka Y, et al
    Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2019 Jun 26. pii: S1525-7304(19)30172.
    PubMed     Text format    

  27. TOLWIN Y, Gillis R, Agmon IN, Shrem NS, et al
    Increased Incidence of Lung Cancer Among Patients With Superficial Transitional Cell Carcinoma: A Potential Risk Cohort for Lung Cancer Screening.
    Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30152.
    PubMed     Text format     Abstract available

  28. SCOTTI V, Bruni A, Perna M, Vasilyeva P, et al
    Response to Letter to the Editor Titled "Surgery or Stereotactic Body Radiotherapy for Early Stage Lung Cancer: What is the Current Evidence?"
    Clin Lung Cancer. 2019 Jun 19. pii: S1525-7304(19)30158.
    PubMed     Text format    

  29. GUO D, Jin F, Jing W, Li M, et al
    Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2019 Jun 15. pii: S1525-7304(19)30150.
    PubMed     Text format     Abstract available

  30. UPRETY D, Arjyal L, Vallatharasu Y, Bista A, et al
    Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis.
    Clin Lung Cancer. 2019 Jun 13. pii: S1525-7304(19)30144.
    PubMed     Text format    

  31. MAZZELLA A, Loi M, Mansuet-Lupo A, Bobbio A, et al
    Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer.
    Clin Lung Cancer. 2019 Jun 13. pii: S1525-7304(19)30145.
    PubMed     Text format     Abstract available

  32. KAMIGAICHI A, Tsutani Y, Fujiwara M, Mimae T, et al
    Postoperative Recurrence and Survival After Segmentectomy for Clinical Stage 0 or IA Lung Cancer.
    Clin Lung Cancer. 2019 Jun 13. pii: S1525-7304(19)30146.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  33. WU J, Jiang L, Zhang F, Huang Y, et al
    Malignant Perivascular Epithelioid Cell Tumor of Lung on FDG PET/CT.
    Clin Nucl Med. 2019 Mar 1. doi: 10.1097/RLU.0000000000002505.
    PubMed     Text format     Abstract available


    Eur J Cancer

  34. YAO ZH, Liao WY, Ho CC, Chen KY, et al
    Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
    Eur J Cancer. 2019;117:107-115.
    PubMed     Text format     Abstract available

  35. ARFFMAN M, Manderbacka K, Suvisaari J, Koivunen J, et al
    The impact of severe mental illness on lung cancer mortality of patients with lung cancer in Finland in 1990-2013: a register-based cohort study.
    Eur J Cancer. 2019;118:105-111.
    PubMed     Text format     Abstract available

  36. GEZELIUS E, Bendahl PO, Goncalves de Oliveira K, Ek L, et al
    Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).
    Eur J Cancer. 2019;118:82-90.
    PubMed     Text format     Abstract available


    Eur Respir J

  37. LU W, Sharma P, Eapen MS, Sohal SS, et al
    Inhaled corticosteroids attenuate epithelial mesenchymal transition: implications for COPD and lung cancer prophylaxis.
    Eur Respir J. 2019;54.
    PubMed     Text format    


    Int J Cancer

  38. BAI L, Shin S, Burnett RT, Kwong JC, et al
    Exposure to ambient air pollution and the incidence of lung cancer and breast cancer in the Ontario Population Health and Environment Cohort (ONPHEC).
    Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32575.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  39. KALAPURAKAL JA, Gopalakrishnan M, Walterhouse DO, Rigsby CK, et al
    Cardiac-Sparing Whole Lung IMRT in Patients With Pediatric Tumors and Lung Metastasis: Final Report of a Prospective Multicenter Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2019;103:28-37.
    PubMed     Text format     Abstract available

  40. HOF SV, Delaney AR, Tekatli H, Twisk J, et al
    Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm.
    Int J Radiat Oncol Biol Phys. 2019;103:259-267.
    PubMed     Text format     Abstract available

  41. STAM B, Kwint M, Guckenberger M, Mantel F, et al
    Subgroup Survival Analysis in Stage I-II NSCLC Patients With a Central Tumor Partly Treated With Risk-Adapted SBRT.
    Int J Radiat Oncol Biol Phys. 2019;103:132-141.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  42. LI Y, Hu S, Xie J, Zhang X, et al
    Effects of surgery on survival of elderly patients with stage I small-cell lung cancer: analysis of the SEER database.
    J Cancer Res Clin Oncol. 2019 Jul 13. pii: 10.1007/s00432-019-02976.
    PubMed     Text format     Abstract available


    J Nucl Med

  43. HEINZMANN K, Nguyen QD, Honess DJ, Smith DM, et al
    Depicting changes in tumor biology in response to cetuximab mono- or combination therapy by apoptosis and proliferation imaging using (18)F-ICMT-11 and 3'-Deoxy-3'-[(18)F]Fluorothymidine ((18)F-FLT) PET.
    J Nucl Med. 2018 May 24. pii: jnumed.118.209304. doi: 10.2967/jnumed.118.209304.
    PubMed     Text format     Abstract available


    J Surg Oncol

  44. NEVALA R, Jaamaa S, Tukiainen E, Tarkkanen M, et al
    Long-term results of surgical resection of lung metastases from soft tissue sarcoma: A single center experience.
    J Surg Oncol. 2019;120:168-175.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  45. GROTH SS, Ripley RT, Carrott P, Burt BM, et al
    Commentary: Usurping the king: A step toward planning a biological checkmate on non-small cell lung carcinoma.
    J Thorac Cardiovasc Surg. 2019 May 30. pii: S0022-5223(19)31150.
    PubMed     Text format    


    J Thorac Oncol

  46. EDELMAN MJ, Redman MW, Albain KS, McGary EC, et al
    Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).
    J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30557.
    PubMed     Text format     Abstract available

  47. MUNDEN RF, Chiles C, Boiselle PM, Sicks JD, et al
    Micronodules Detected on CT during the NLST: Prevalence and Relation to Positive Studies and Lung Cancer.
    J Thorac Oncol. 2019 Jun 20. pii: S1556-0864(19)30481.
    PubMed     Text format     Abstract available

  48. FUJINO T, Kobayashi Y, Suda K, Koga T, et al
    Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
    J Thorac Oncol. 2019 Jul 3. pii: S1556-0864(19)30551.
    PubMed     Text format     Abstract available

  49. BENITEZ JC, Mezquita L, Colle R, Tselikas KL, et al
    Hepatic Intra-Arterial Chemotherapy with Immunotherapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30556.
    PubMed     Text format    


    JAMA Oncol

  50. BAUML JM, Mick R, Ciunci C, Aggarwal C, et al
    Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
    JAMA Oncol. 2019 Jul 11. pii: 2738063. doi: 10.1001/jamaoncol.2019.1449.
    PubMed     Text format     Abstract available

  51. THEELEN WSME, Peulen HMU, Lalezari F, van der Noort V, et al
    Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2019 Jul 11. pii: 2738064. doi: 10.1001/jamaoncol.2019.1478.
    PubMed     Text format     Abstract available


    Lancet Oncol

  52. HERBST RS, Arkenau HT, Santana-Davila R, Calvo E, et al
    Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Lancet Oncol. 2019 Jul 10. pii: S1470-2045(19)30458.
    PubMed     Text format     Abstract available


    Lancet Respir Med

  53. BOSSE Y, Martel S
    Germline variants invited to lung cancer screening.
    Lancet Respir Med. 2019 Jul 17. pii: S2213-2600(19)30188.
    PubMed     Text format    

  54. DAI J, Lv J, Zhu M, Wang Y, et al
    Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.
    Lancet Respir Med. 2019 Jul 17. pii: S2213-2600(19)30144.
    PubMed     Text format     Abstract available


    Lung Cancer

  55. FRANCAVIGLIA I, Magliacane G, Lazzari C, Grassini G, et al
    Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Lung Cancer. 2019;134:225-232.
    PubMed     Text format     Abstract available

  56. VANNITAMBY A, Hendry S, Irving L, Steinfort D, et al
    Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
    Lung Cancer. 2019;134:233-237.
    PubMed     Text format     Abstract available

  57. ACKERMANN CJ, Reck M, Paz-Ares L, Barlesi F, et al
    First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
    Lung Cancer. 2019;134:245-253.
    PubMed     Text format     Abstract available

  58. BALATA H, Evison M, Sharman A, Crosbie P, et al
    CT screening for lung cancer: Are we ready to implement in Europe?
    Lung Cancer. 2019;134:25-33.
    PubMed     Text format     Abstract available

  59. LIU Z, Liang H, Lin J, Cai X, et al
    The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer.
    Lung Cancer. 2019;134:218-224.
    PubMed     Text format     Abstract available

  60. BOADA M, Guzman R, Montesinos M, Libreros A, et al
    UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY.
    Lung Cancer. 2019;134:254-258.
    PubMed     Text format     Abstract available

  61. MELOSKY B, Juergens R, McLeod D, Leighl N, et al
    Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Lung Cancer. 2019;134:259-267.
    PubMed     Text format     Abstract available

  62. VAN DE VEN M, Retel VP, Koffijberg H, van Harten WH, et al
    Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.
    Lung Cancer. 2019;134:34-41.
    PubMed     Text format     Abstract available

  63. HELLYER JA, Stehr H, Das M, Padda SK, et al
    Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Lung Cancer. 2019;134:42-45.
    PubMed     Text format     Abstract available

  64. BOUSEMA JE, van Dorp M, Hoeijmakers F, Huijbregts IA, et al
    Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis.
    Lung Cancer. 2019;134:52-58.
    PubMed     Text format     Abstract available

  65. GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
    Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme.
    Lung Cancer. 2019;134:66-71.
    PubMed     Text format     Abstract available

  66. KIM H, Goo JM, Paeng JC, Kim YT, et al
    Evaluation of maximum standardized uptake value at fluorine-18 fluorodeoxyglucose positron emission tomography as a complementary T factor in the eighth edition of lung cancer stage classification.
    Lung Cancer. 2019;134:151-157.
    PubMed     Text format     Abstract available

  67. HARAGAN A, Field JK, Davies MPA, Escriu C, et al
    Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
    Lung Cancer. 2019;134:79-84.
    PubMed     Text format     Abstract available

  68. ZUGAZAGOITIA J, Gomez-Rueda A, Jantus-Lewintre E, Isla D, et al
    Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Lung Cancer. 2019;134:72-78.
    PubMed     Text format     Abstract available

  69. CAPELLETTO E, Migliorino MR, Morabito A, Chiari R, et al
    Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.
    Lung Cancer. 2019;134:210-217.
    PubMed     Text format     Abstract available

  70. YOSHIMURA K, Inoue Y, Karayama M, Tsuchiya K, et al
    Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Lung Cancer. 2019;134:202-209.
    PubMed     Text format     Abstract available

  71. DING PN, Becker TM, Bray VJ, Chua W, et al
    The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Lung Cancer. 2019;134:187-193.
    PubMed     Text format     Abstract available

  72. MANJUNATH Y, Upparahalli SV, Suvilesh KN, Avella DM, et al
    Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.
    Lung Cancer. 2019;134:147-150.
    PubMed     Text format     Abstract available

  73. GIBSON AJW, Li H, D'Silva A, Elegbede AA, et al
    Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
    Lung Cancer. 2019;134:141-146.
    PubMed     Text format     Abstract available

  74. DAFNI U, Tsourti Z, Vervita K, Peters S, et al
    Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Lung Cancer. 2019;134:127-140.
    PubMed     Text format     Abstract available

  75. SANTO A, Pilotto S, Galetta D, Grossi F, et al
    Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.
    Lung Cancer. 2019;134:121-126.
    PubMed     Text format     Abstract available

  76. ZHANG B, Niu X, Zhang Q, Wang C, et al
    Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Lung Cancer. 2019;134:108-116.
    PubMed     Text format     Abstract available

  77. NAKAMURA H, Sugano M, Miyashita T, Hashimoto H, et al
    Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells.
    Lung Cancer. 2019;134:100-107.
    PubMed     Text format     Abstract available

  78. HAYASHI H, Iihara H, Hirose C, Fukuda Y, et al
    Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
    Lung Cancer. 2019;134:1-6.
    PubMed     Text format     Abstract available

  79. MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
    Corrigendum to "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos" [Lung Cancer, 131 (May) (2019) 23-30].
    Lung Cancer. 2019;134:279.
    PubMed     Text format    

  80. TAN KS
    Misclassification of the actual causes of death and its impact on analysis: A case study in non-small cell lung cancer.
    Lung Cancer. 2019;134:16-24.
    PubMed     Text format     Abstract available

  81. KASAHARA N, Kaira K, Yamaguchi K, Masubuchi H, et al
    Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer.
    Lung Cancer. 2019;134:180-186.
    PubMed     Text format     Abstract available

  82. DIETEL M, Savelov N, Salanova R, Micke P, et al
    Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
    Lung Cancer. 2019;134:174-179.
    PubMed     Text format     Abstract available

  83. OWEN DH, Williams TM, Bertino EM, Mo X, et al
    Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
    Lung Cancer. 2019;134:167-173.
    PubMed     Text format     Abstract available

  84. HYUN MH, Lee ES, Eo JS, Kim S, et al
    Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
    Lung Cancer. 2019;134:158-166.
    PubMed     Text format     Abstract available


    Mol Cancer Ther

  85. ANANTHARAJAN J, Zhou H, Zhang L, Hotz T, et al
    Structural and functional analyses of an allosteric Eya2 phosphatase inhibitor that has on target effects in human lung cancer cells.
    Mol Cancer Ther. 2019 Jul 8. pii: 1535-7163.MCT-18-1239.
    PubMed     Text format     Abstract available


    Mol Carcinog

  86. LAWSON J, Dickman C, Towle R, Jabalee J, et al
    Extracellular vesicle secretion of miR-142-3p from lung adenocarcinoma cells induces tumor promoting changes in the stroma through cell-cell communication.
    Mol Carcinog. 2019;58:376-387.
    PubMed     Text format     Abstract available


    Nat Med

  87. WANG Z, Yip LY, Lee JHJ, Wu Z, et al
    Methionine is a metabolic dependency of tumor-initiating cells.
    Nat Med. 2019;25:825-837.
    PubMed     Text format     Abstract available

  88. RODON J, Soria JC, Berger R, Miller WH, et al
    Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
    Nat Med. 2019;25:751-758.
    PubMed     Text format     Abstract available


    Oncogene

  89. NOEPARAST A, Giron P, Noor A, Bahadur Shahi R, et al
    CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.
    Oncogene. 2019 Jul 8. pii: 10.1038/s41388-019-0866.
    PubMed     Text format     Abstract available

  90. RAOOF S, Mulford IJ, Frisco-Cabanos H, Nangia V, et al
    Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
    Oncogene. 2019 Jul 19. pii: 10.1038/s41388-019-0887.
    PubMed     Text format     Abstract available

  91. YAO S, Huang HY, Han X, Ye Y, et al
    Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation.
    Oncogene. 2019 Jul 18. pii: 10.1038/s41388-019-0889.
    PubMed     Text format     Abstract available


    Oncol Rep

  92. SHI C, Xu L, Tang Z, Zhang W, et al
    Knockdown of Nemolike kinase promotes metastasis in nonsmallcell lung cancer.
    Oncol Rep. 2019 Jul 9. doi: 10.3892/or.2019.7226.
    PubMed     Text format     Abstract available

  93. TIAN Y, Yu M, Sun L, Liu L, et al
    Long noncoding RNA00887 reduces the invasion and metastasis of nonsmall cell lung cancer by causing the degradation of miRNAs.
    Oncol Rep. 2019 Jul 11. doi: 10.3892/or.2019.7228.
    PubMed     Text format     Abstract available


    PLoS One

  94. POVSIC M, Enstone A, Wyn R, Kornalska K, et al
    Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR).
    PLoS One. 2019;14:e0219622.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: